|
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease of the heart muscle As it progresses, the heart can become unable to adequately squeeze to pump blood out of the heart, ultimately leading to heart failure
- Advancing access to clinical trials for cardiomyopathy
As part of this work, the Association today announced an initiative to improve education, outreach and access to clinical trials for gene editing therapies for transthyretin amyloid cardiomyopathy (ATTR-CM) ATTR-CM is a progressive and often underdiagnosed condition that disproportionately affects older adults and certain racial and ethnic groups
- Guidelines in a New Era for Cardiac Amyloidosis
For instance, low QRS voltage on ECG is a late finding in cardiac amyloidosis present in fewer than half of people with biopsy-proven ATTR-CM, in contrast with earlier studies recommending low QRS voltage on ECG as an adjunct for screening before endomyocardial biopsy1, 3, 4
- Transthyretin Amyloidosis (ATTR) for Professionals
Video webinar series helps instructs healthcare professionals in improving care and treatment for patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Your Guide to Gene Editing and Clinical Trials for Heart Health
To join a gene editing trial, a person usually needs to meet certain requirements, such as: 1 Having a confirmed diagnosis of a genetic condition that affects the heart, like ATTR-CM 2 Having specific health conditions and or a genetic marker (a tiny part of your genes that can show where something important is located) that match the trial’s
- Microsoft PowerPoint - AHA_hATTR_Identification_Khouri FINAL
ATTR-CM: Severity Relevance to Practice Diagnostic delays are common and diagnosis in ATTR-CM and diagnosis is often made at a more advanced stage
- Hereditary Transthyretin-Mediated Amyloidosis (hATTR) Clinical Clues . . .
The list of clinical clues and diagnostic testing provided in this quick reference guide are intended to promote earlier identification and accurate diagnosis of ATTR amyloidosis, with subsequent genetic testing to determine if there is a genetic cause
- Microsoft PowerPoint - Multidisciplinary team-based care for patients . . .
Cardiac QOL is poor in patients with ATTR-CM and generally worse at baseline than patients enrolled in contemporary heart failure trials A multidisciplinary team is needed for diagnosis and longitudinal care of patients with amyloidosis Tips to start and maintain an amyloidosis program
|
|
|